This is a good piece of news , this reduces manual labor in designing the patient specific implants and would significantly reduce the time to patient delivery. The latter being something surgeons will prefer as it means easier planning and more volume.
One of the issues with OSX is many products from its pipeline are still years away, this is a bottom draw stock but should revenues increase from the current product portfolio (as anticipated by the CEO) then we could see a nice re-rate, the cash burn is relatively small and it would not take much to flip a profit here.
The partnership with National Singapore Dental is quite significant and not fully appreciated by the market IMO, this is just shy of $19M worth of funding which involves advancing OSX's technology. If you look back at the recent releases you start noticing management have been chipping away at penetrating the china market. They have secured patents in China and the most recent Hong Kong pilot program allows them a gateway into China via the greater bay area.
Watching closely to see what happens with revenues, management need to work closely with their distributors to ensure the right incentives are in place. OSX products have very good margins so lots of net profit to be shared, though the challenge is the products are low cost so it's game of quantity/volume. They need to penetrate more markets/countries and partner with high quality distributors else establish their own sales team (if it's economically viable).
(20min delay)